Literatur
- 1
Abenhaim L, Moride Y, Brenot F. et al .
Appetite-suppressant drugs and the risk
of primary pulmonary hypertension. International Primary Pulmonary
Hypertension Study Group.
N Engl J Med.
1996;
335
609-616
- 2
Baseman D G, O’Suilleabhain P E, Reimold S C. et al .
Pergolide use
in Parkinson disease is associated with cardiac valve regurgitation.
Neurology.
2004;
63
301-304
- 3
Baumann M H, Ayestas M A, Dersch C M. et al .
Effects of phentermine and
fenfluramine on extracellular dopamine and serotonin in rat nucleus
accumbens: therapeutic implications.
Synapse.
2000;
36
102-113
- 4
Brenot F, Herve P, Petitpretz P. et al .
Primary pulmonary hypertension and fenfluramine
use.
Br Heart J.
1993;
70
537-541
- 5
Cannistra L B, Davis S M, Bauman A G.
Valvular heart disease associated with dexfenfluramine.
N Engl J Med.
1997;
337
636
- 6
Connolly H M, Crary J L, McGoon M D. et al .
Valvular heart disease associated
with fenfluramine-phentermine.
N Engl J Med.
1997;
337
581-588
- 7
Creutzig A.
[Ergotamine-induced heart valve fibrosis and coronary microangiopathy?].
Dtsch Med Wochenschr.
1992;
117
1736
- 8
Danoff S K, Grasso M E, Terry P B. et al .
Pleuropulmonary disease
due to pergolide use for restless legs syndrome.
Chest.
2001;
120
313-316
- 9
Devereux R B.
Appetite suppressants and valvular heart disease.
N Engl
J Med.
1998;
339
765-766
- 10
Droogmans S, Cosyns B, D’haenen H. et al .
Possible association between 3,4-methylenedioxymethamphetamine
abuse and valvular heart disease.
Am J Cardiol.
2007;
100
1442-1445
- 11
Droogmans S, Franken P R, Garbar C. et al .
In vivo model of drug-induced valvular
heart disease in rats: pergolide-induced valvular heart disease
demonstrated with echocardiography and correlation with pathology.
Eur Heart J.
2007;
28
2156-2162
- 12
Dupuy D, Lesbre J P, Gerard P. et al .
Valvular heart disease in patients with
Parkinson’s disease treated with pergolide. Course following treatment
modifications.
J Neurol.
2008;
255
1045-1048
- 13
Faber L.
[Ergotamine-induced heart valve fibrosis].
Dtsch Med Wochenschr.
1993;
118
205
- 14
Fitzgerald L W, Burn T C, Brown B S. et al .
Possible role of valvular
serotonin 5-HT(2B) receptors in the cardiopathy associated with
fenfluramine.
Mol Pharmacol.
2000;
57
75-81
- 15
Gardin J M, Weissman N J, Leung C. et al .
Clinical and echocardiographic follow-up
of patients previously treated with dexfenfluramine or phentermine/fenfluramine.
JAMA.
2001;
286
2011-2014
- 16
Graham D J, Green L.
Further cases of valvular
heart disease associated with fenfluramine-phentermine.
N
Engl J Med.
1997;
337
635
- 17
Gustafsson B I, Tommeras K, Nordrum I. et al .
Long-term serotonin administration induces
heart valve disease in rats.
Circulation.
2005;
111
1517-1522
- 18
Hendrikx M, Van Dorpe J, Flameng W. et al .
Aortic and mitral valve disease induced
by ergotamine therapy for migraine: a case report and review of
the literature.
J Heart Valve Dis.
1996;
5
235-237
- 19
Horvath J, Fross R D, Kleiner-Fisman G. et al .
Severe multivalvular heart disease:
a new complication of the ergot derivative dopamine agonists.
Mov Disord.
2004;
19
656-662
- 20
Howard R J, Drobac M, Rider W D. et al .
Carcinoid heart disease: diagnosis by two-dimensional
echocardiography.
Circulation.
1982;
66
1059-1065
- 21
Kastelik J A, Aziz I, Greenstone M A. et al .
Pergolide-induced lung disease in patients
with Parkinson’s disease.
Respir Med.
2002;
96
548-550
- 22
Kaumann A J.
Do human atrial 5-HT4 receptors mediate arrhythmias?.
Trends
Pharmacol Sci.
1994;
15
451-455
- 23
Kaumann A J, Levy F O.
5-hydroxytryptamine
receptors in the human cardiovascular system.
Pharmacol
Ther.
2006;
111
674-706
- 24
Khan M A, Herzog C A, St Peter J V. et al .
The prevalence of cardiac
valvular insufficiency assessed by transthoracic echocardiography
in obese patients treated with appetite-suppressant drugs.
N
Engl J Med.
1998;
339
713-718
- 25
Kulke M H, Mayer R J.
Carcinoid tumors.
N Engl J Med.
1999;
340
858-868
- 26
Ling L H, Ahlskog J E, Munger T M. et al .
Constrictive pericarditis
and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline)
for Parkinson’s disease.
Mayo Clin Proc.
1999;
74
371-375
- 27
Mark E J, Patalas E D, Chang H T. et al .
Fatal pulmonary hypertension associated
with short-term use of fenfluramine and phentermine.
N Engl
J Med.
1997;
337
602-606
- 28
Moller J E, Connolly H M, Rubin J. et al .
Factors associated with progression of
carcinoid heart disease.
N Engl J Med.
2003;
348
1005-1015
- 29
Moyssakis I E, Rallidis L S, Guida G F. et al .
Incidence and evolution
of carcinoid syndrome in the heart.
J Heart Valve Dis.
1997;
6
625-630
- 30
Nutt J G, Wooten G F.
Clinical practice.
Diagnosis and initial management of Parkinson’s disease.
N Engl J Med.
2005;
353
1021-1027
- 31
Pellikka P A, Tajik A J, Khandheria B K. et al .
Carcinoid heart disease.
Clinical and echocardiographic spectrum in 74 patients.
Circulation.
1993;
87
1188-1196
- 32
Peralta C, Wolf E, Alber H. et
al .
Valvular heart disease in Parkinson’s disease
vs. controls: An echocardiographic study.
Mov Disord.
2006;
21
1109-1113
- 33
Pinero A, Marcos-Alberca P, Fortes J.
Cabergoline-related severe restrictive mitral regurgitation.
N Engl J Med.
2005;
353
1976-1977
- 34
Pritchett A M, Morrison J F, Edwards W D. et al .
Valvular heart disease in patients
taking pergolide.
Mayo Clin Proc.
2002;
77
1280-1286
- 35
Rasmussen V G, Poulsen S H, Dupont E. et al .
Ergotamine-derived dopamine agonists and
left ventricular function in Parkinson patients: systolic and diastolic
function studied by conventional echocardiography, tissue Doppler
imaging, and two-dimensional speckle tracking.
Eur J Echocardiogr.
2008;
9
803-808
- 36
Rasmussen V G, Poulsen S H, Dupont E. et al .
Heart valve disease associated with treatment
with ergot-derived dopamine agonists: a clinical and echocardiographic
study of patients with Parkinson’s disease.
J
Intern Med.
2008;
263
90-98
- 37
Redfield M M, Nicholson W J, Edwards W D. et al .
Valve disease associated
with ergot alkaloid use: echocardiographic and pathologic correlations.
Ann Intern Med.
1992;
117
50-52
- 38
Robiolio P A, Rigolin V H, Wilson J S. et al .
Carcinoid heart disease.
Correlation of high serotonin levels with valvular abnormalities
detected by cardiac catheterization and echocardiography.
Circulation.
1995;
92
790-795
- 39
Roth B L.
Drugs and valvular heart disease.
N Engl J Med.
2007;
356
6-9
- 40
Rothman R B, Baumann M H.
Therapeutic
and adverse actions of serotonin transporter substrates.
Pharmacol
Ther.
2002;
95
73-88
- 41
Rothman R B, Baumann M H, Savage J E. et al .
Evidence for possible involvement
of 5-HT(2B) receptors in the cardiac valvulopathy associated with
fenfluramine and other serotonergic medications.
Circulation.
2000;
102
2836-2841
- 42
Sakai D, Murakami M, Kawazoe K. et al .
Ileal carcinoid tumor complicating carcinoid
heart disease and secondary retroperitoneal fibrosis.
Pathol
Int.
2000;
50
404-411
- 43
Schade R, Andersohn F, Suissa S. et al .
Dopamine agonists and the risk of cardiac-valve
regurgitation.
N Engl J Med.
2007;
356
29-38
- 44
Serratrice J, Disdier P, Habib G. et al .
Fibrotic valvular heart disease subsequent
to bromocriptine treatment.
Cardiol Rev.
2002;
10
334-336
- 45
Setola V, Hufeisen S J, Grande-Allen K J. et al .
3,4-methylenedioxymethamphetamine
(MDMA, „Ecstasy”) induces fenfluramine-like proliferative
actions on human cardiac valvular interstitial cells in vitro.
Mol Pharmacol.
2003;
63
1223-1229
- 46
Setola V, Roth B L.
Screening the
receptorome reveals molecular targets responsible for drug-induced
side effects: focus on ‘fen-phen’.
Expert
Opin Drug Metab Toxicol.
2005;
1
377-387
- 47
Shively B K, Roldan C A, Gill E A. et al .
Prevalence and determinants
of valvulopathy in patients treated with dexfenfluramine.
Circulation.
1999;
100
2161-2167
- 48
Steffee C H, Singh H K, Chitwood W R.
Histologic changes in three explanted native
cardiac valves following use of fenfluramines.
Cardiovasc
Pathol.
1999;
8
245-253
- 49
Van Camp G, Flamez A, Cosyns B. et al .
Heart valvular disease in patients with
Parkinson’s disease treated with high-dose pergolide.
Neurology.
2003;
61
859-861
- 50
Van Camp G, Flamez A, Cosyns B. et al .
Treatment of Parkinson’s disease
with pergolide and relation to restrictive valvular heart disease.
Lancet.
2004;
363
1179-1183
- 51
Weissman N J, Tighe Jr J F, Gottdiener J S. et al .
An assessment
of heart-valve abnormalities in obese patients taking dexfenfluramine,
sustained-release dexfenfluramine, or placebo. Sustained-Release
Dexfenfluramine Study Group.
N Engl J Med.
1998;
339
725-732
- 52
Wilke A, Hesse H, Hufnagel G. et
al .
Mitral, aortic and tricuspid valvular heart disease
associated with ergotamine therapy for migraine.
Eur Heart
J.
1997;
18
701
- 53
Zanettini R, Antonini A, Gatto G. et al .
Valvular heart disease and the use of dopamine
agonists for Parkinson’s disease.
N Engl J Med.
2007;
356
39-46
Dr. med. Daniela Blaschke
Charité – Universitätsmedizin
Berlin, Campus Virchow-Klinikum, Medizinische Klinik
mit Schwerpunkt Kardiologie
Augustenburger Platz
1
13353 Berlin
Telefon: 030/450653366
Fax: 030/450553957
eMail: daniela.blaschke@charite.de
